| Literature DB >> 35101807 |
Vishal Kumar Parida1, Divyanshu Sikarwar2, Abhradeep Majumder1, Ashok Kumar Gupta3.
Abstract
Hospitals release significant quantities of wastewater (HWW) and biomedical waste (BMW), which hosts a wide range of contaminants that can adversely affect the environment if left untreated. The COVID-19 outbreak has further increased hospital waste generation over the past two years. In this context, a thorough literature study was carried out to reveal the negative implications of untreated hospital waste and delineate the proper ways to handle them. Conventional treatment methods can remove only 50%-70% of the emerging contaminants (ECs) present in the HWW. Still, many countries have not implemented suitable treatment methods to treat the HWW in-situ. This review presents an overview of worldwide HWW generation, regulations, and guidelines on HWW management and highlights the various treatment techniques for efficiently removing ECs from HWW. When combined with advanced oxidation processes, biological or physical treatment processes could remove around 90% of ECs. Analgesics were found to be more easily removed than antibiotics, β-blockers, and X-ray contrast media. The different environmental implications of BMW have also been highlighted. Mishandling of BMW can spread infections, deadly diseases, and hazardous waste into the environment. Hence, the different steps associated with collection to final disposal of BMW have been delineated to minimize the associated health risks. The paper circumscribes the multiple aspects of efficient hospital waste management and may be instrumental during the COVID-19 pandemic when the waste generation from all hospitals worldwide has increased significantly.Entities:
Keywords: Advanced oxidation processes; Biodegradation; Biomedical waste management; Emerging contaminants; Hospital wastewater treatment; Legislations
Mesh:
Substances:
Year: 2022 PMID: 35101807 PMCID: PMC8789570 DOI: 10.1016/j.jenvman.2022.114609
Source DB: PubMed Journal: J Environ Manage ISSN: 0301-4797 Impact factor: 8.910
Fig. 1Year-wise publications of research articles on different (a) ECs found in HWW and (b) various categories of BMW, respectively. The cumulative number of publications and corresponding S-curve for (c) HWW and (d) BMW, respectively.
The number of in-patients beds and the quantity of wastewater generated by different hospitals and health care facilities worldwide based on global national income (GNI), World Bank.
| Class | Country | No. of beds | Wastewater generated (m3/d) | Reference |
|---|---|---|---|---|
| Australia | 190 | 138 | ||
| Belgium | 641 | 250 | ( | |
| Belgium | 1048 | 600 | ( | |
| Denmark | 691 | 360–500 | ||
| France | 750 | 450 | ||
| France | – | 651.6 | ||
| Japan | 477 | 460 | ||
| Netherlands | 1076 | 240 | ||
| Portugal | 1120 | 1000 | ||
| Spain | 750 | 429 | ||
| Spain | 850 | 400 | ||
| Germany | 1274 | 617 | ||
| Germany | 580 | 200 | ||
| Germany | 340 | 768 | ||
| Italy | 900 | 630 | ||
| Italy | 300–900 | 382 | ||
| Italy | 300 | 180 | ||
| Saudi Arabia | 215–300 | 763 | ||
| Switzerland | 1781 | 640 | ||
| Switzerland | 346 | 187 | ||
| Switzerland | 415 | 380 | ||
| Brazil | 180 | 150 | ||
| Brazil | – | 432 | ||
| Brazil | 328 | 190 | ( | |
| Brazil | 322 | 220 | ||
| Brazil | – | 326 | ||
| China | – | 575 | ||
| Costa Rica | 100 | 84.5 | ( | |
| Mauritius | 556 | 500 | ||
| Turkey | 780 | 300 | ||
| Turkey | 750 | 344 | ||
| Turkey | 201 | 92 | ||
| Thailand | – | 350 | ||
| Ethiopia | 305 | 143 | ||
| Ghana | 413 | 8.3 | ||
| India | 310 | 50 | ||
| India | – | 50 | ||
| India | 200 | 50 | ||
| Iran | 130 | 47 | ||
| Iran | 85 | 14.5 | ||
| Morocco | 400 | 367 | ||
| Nigeria | 600 | 100 | ||
| Pakistan | – | 0.5535 m3/bed/day | ||
| Sri Lanka | 1453 | 200 |
Fig. 2Generation of different contaminants from the hospital and healthcare facilities and their subsequent pathway into different aqueous environments.
Fig. 3Various treatment approaches for HWW management in different countries. [Adapted from (Akiba et al., 2015; Akter et al., 2012; Ali et al., 2013; Ashfaq et al., 2016; Azuma et al., 2016; Beyene and Redaie, 2011; Duong et al., 2008; El-gawad et al., 2011; Iweriebor et al., 2015; Kajitvichyanukul and Suntronvipart, 2006; Lin et al., 2010; Messrouk et al., 2014; Mubedi et al., 2013; Nasr and Yazdanbakhsh, 2008; Prabhakaranunni Prabhasankar et al., 2016; Prayitno et al., 2012; Shrestha et al., 2001; Sim et al., 2013; Thompson et al., 2013; Verlicchi, 2018):].
Fig. 4Box and whisker plots showing variation in the worldwide concentration of (a) different HWW physicochemical parameters and (b) selected ECs in HWW effluents/hospital WWTPs influents (where n represents sample size). (c) Box and whisker plots showing variation in the removal of selected ECs in HWW by different treatment methods and (d) performance of various treatment methods in terms of removal of ECs from HWW [Data source: Table S1 for (a) Table S2 for (b), Table S3 for (c) and (d) in Supplementary Material].
The guidelines and regulations including the discharge standards related to HWW treatment in different countries.
| Guidelines/Regulation | Organization/country | Type of disposal/discharge< | pH | BOD (mg/L) | COD (mg/L) | Suspended Solids (mg/L) | Oil and Grease (mg/L) | Ammonia nitrogen (as N) (mg/L) | Total phosphorous (mg/L) | Bio-assay test/ | References |
|---|---|---|---|---|---|---|---|---|---|---|---|
| The Bio-Medical Waste (Management and Handling) Rules, 1998 | India | On-site treated HWW before discharge to surface water | Not-indicated | ( | |||||||
| For HWW before discharged into municipal WWTP | 5.5–9.0 | 350 | – | 600 | 20 | 50 | – | 90% survival of fish after 96 h in 100% effluent | |||
| Direct discharge to surface water after pre-treatment | 6.5–9.5 | 30 | 250 | 100 | 10 | – | – | 90% survival of fish after 96 h in 100% effluent | |||
| DRP No. 227/2011 on simplification on environmental law, 2011 | Italy | On-site treated HWW before discharge to surface water | Not-indicated | ||||||||
| For HWW before discharged into municipal WWTP | 5.5–9.5 | ≤300 | ≤700 | ≤700 | ≤ | ≤50 | ≤30 | <5000 UFC/100 mL | |||
| Direct discharge to surface water after pre-treatment | 5.5–9.5 | ≤40 | ≤160 | ≤80 | ≤20 | ≤15 | ≤10 | <5000 UFC/100 mL | |||
| National Standard of the People's Republic of China Integrated Wastewater Discharge Standard GB 8978, 1996 | China | On-site treated HWW before discharge to surface water | Not-indicated | ( | |||||||
| For HWW before discharged into municipal WWTP | 6–9 | ≤300 | ≤500 | ≤400 | – | – | ≤0.3 | Bacteria count: ≤ 1000–5000 pieces/L | |||
| Direct discharge to surface water after pre-treatment | 6–9 | 100–150 | 100–150 | 70–150 | – | 15–25 | ≤0.1 | Bacteria count: ≤ 100–500 pieces/L | |||
| National Council for the Environment-CONAMA. | Brazil | On-site treated HWW before discharge to surface water | 5–9 | ≤120 | – | Sediment materials: up to 1 mL/L in a 1-h cone test (Imhoff) | ≤100 | – | – | – | ( |
| HWW before discharged into municipal WWTP | Not-indicated | ||||||||||
| Direct discharge to surface water after pre-treatment | 5–9 | 60% of untreated sewage | – | Sediment materials: up to 1 mL/L in a 1-h cone test (Imhoff) | Mineral oil: ≤ 20 | ≤20 | – | – | |||
| Decreto n.26,042-S- MINAE on management of discharges and reuses of effluents, 1997 | Spain | On-site treated HWW before discharge to surface water | Not-indicated | ||||||||
| For HWW before discharged into municipal WWTP | 6–9 | ≤300 | ≤1000 | ≤500 | ≤100 | ≤0.1 | – | ||||
| Direct discharge to surface water after pre-treatment | 5–9 | – | – | ≤1 | – | – | ≤0.1 | ≤1000 CFC/100 mL | |||
| Effluent Guidelines and Standards (CFR 40) (Part – 460, Hospital point source) (US EPA), 1976 | USA | On-site treated HWW before discharge to surface water | Not-indicated | ||||||||
| For HWW before discharged into municipal WWTP | Not-indicated | ||||||||||
| Direct discharge to surface water after pre-treatment | 6–9 | 41 kg/1000 occupied beds/day | – | 55.6 kg/1000 occupied beds/day | – | – | – | – | |||
| Wastewater Ordinance (AbwV), 2004 | Germany | On-site treated HWW before discharge to surface water | – | 15–40 | 75–150 | ≤35 | – | ≤10 | 1–2 | – | ( |
| For HWW before discharged into municipal WWTP | Not-indicated | ||||||||||
| Direct discharge to surface water after pre-treatment | Not-indicated | ||||||||||
| The Urban Waste Water Treatment (England and Wales) Regulations (SI-2841), 1994 | England and Wales | On-site treated HWW before discharge to surface water | – | 25 | 125 | – | – | Total N: 15 mg/L (population 10,000–100,000), 10 mg/L (population >100,000), | 2 mg/L (population 10,000–100,000), 1 mg/L (population >100,000), | – | ( |
| For HWW before discharged into municipal WWTP | Not-indicated | ||||||||||
| Direct discharge to surface water after pre-treatment | Not-indicated | ||||||||||
| National technical regulations QCVN 28:2010/BTNTM on Healthcare wastewater effluent quality, Environmental and Social Management Framework, 2010 | Vietnam | On-site treated HWW before discharge to surface water | Not-indicated | ||||||||
| For HWW before discharged into municipal WWTP | 6.5–8.5 | ≤50 | ≤100 | ≤100 | ≤20 | ≤10 | ≤10 | Total coliform: 5000 (MPN/100 mL) | |||
| Direct discharge to surface water after pre-treatment | 6.5–8.5 | ≤30 | ≤50 | ≤50 | ≤10 | ≤5 | ≤6 | Total coliform: 3000 (MPN/100 mL) | |||
| Safe Management of Wastes from Healthcare Activities (2014 | WHO | On-site treated HWW before discharge to surface water | Yes, if municipal WWTP failed to remove 95% bacteria load from HWW | ||||||||
| For HWW before discharged into municipal WWTP | Yes, if municipal WWTP achieve to remove 95% bacteria load from HWW | ||||||||||
| Direct discharge to surface water after pre-treatment | Not indicated | ||||||||||
| European Union Directive 91/271/EEC on urban wastewater treatment, 1991 | EU | On-site treated HWW before discharge to surface water | Not indicated | ||||||||
| For HWW before discharged into municipal WWTP | Requires pre-authorization before discharging MWW into urban sewers (as in certain country is considered the hospital effluent) | ||||||||||
| Direct discharge to surface water after pre-treatment | Not indicated | ||||||||||
| European Union Directive 2008/98/EC on waste, 2008 | EU | On-site treated HWW before discharge to surface water | Not indicated | ||||||||
| For HWW before discharged into municipal WWTP | HWW containing PhACs and PPCPs must not be discharged to municipal sewers | ||||||||||
| Direct discharge to surface water after pre-treatment | Not indicated | ||||||||||
DRP No. 227/2011 on simplification on environmental law, 2011(Italy).
Legislative Decree No. 152/2006 on environmental protection, 2006 (Italy).
Predicted no-effect concentrations (PNECs) values for ecotoxicity to aquatic organisms and calculated drinking water equivalent limit (DWEL) values of selected ECs.
| ECs | PNEC (μg/L) | References | ADI (mg/kg/day) | References | DWEL (mg/L) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Body weight (kg) | ||||||||||
| 41–50 | 51–60 | 61–70 | 71–80 | 81–90 | 91–100 | |||||
| Paracetamol | 1.4 | 0.34 | 5.46–6.67 | 6.80–8.00 | 8.13–9.33 | 9.47–10.67 | 10.80–12.00 | 12.13–13.33 | ||
| Ibuprofen | 1.65 | 0.11 | 1.77–2.16 | 2.20–2.59 | 2.63–3.02 | 3.06–3.45 | 3.49–3.88 | 3.92–4.31 | ||
| Diclofenac | 0.05 | 0.0016 | 0.026–0.031 | 0.032–0.037 | 0.038–0.044 | 0.045–0.050 | 0.051–0.056 | 0.057–0.063 | ||
| Salicylic acid | 1.28 | 0.75 | 12.06–14.71 | 15.00–17.65 | 17.94–20.59 | 20.88–23.53 | 23.82–26.47 | 26.76–29.41 | ||
| Naproxen | 0.33 | 0.046 | 0.74–0.90 | 0.92–1.08 | 1.10–1.26 | 1.28–1.44 | 1.46–1.62 | 1.64–1.80 | ||
| Ciprofloxacin | 1.2 | 0.0016 | 0.026–0.031 | 0.032–0.037 | 0.038–0.044 | 0.045–0.050 | 0.051–0.056 | 0.057–0.063 | ||
| Erythromycin | 0.02 | 0.04 | 0.64–0.78 | 0.80–0.94 | 0.96–1.10 | 1.11–1.25 | 1.27–1.41 | 1.43–1.57 | ||
| Norfloxacin | 0.16 | 0.19 | 3.05–3.72 | 3.80–4.47 | 4.54–5.21 | 5.29–5.96 | 6.04–6.71 | 6.78–7.45 | ||
| Trimethoprim | 0.16 | 0.0042 | 0.067–0.082 | 0.084–0.099 | 0.100–0.115 | 0.117–0.132 | 0.133–0.148 | 0.150–0.165 | ||
| Ofloxacin | 0.016 | 2 | 32.16–39.21 | 40.00–47.06 | 47.84–54.90 | 55.69–62.75 | 63.53–70.59 | 71.37–78.43 | ||
| Tetracycline | – | – | 0.03 | 0.48–0.59 | 0.60–0.71 | 0.72–0.82 | 0.84–0.94 | 0.95–1.06 | 1.07–1.18 | |
| Azithromycin | – | – | 0.011 | 0.18–0.21 | 0.22–0.25 | 0.26–0.30 | 0.31–0.34 | 0.35–0.38 | 0.39–0.43 | |
| Sulfamethoxazole | 0.027 | 0.13 | 2.09–2.55 | 2.60–3.06 | 3.11–3.57 | 3.62–4.08 | 4.13–4.59 | 4.64–5.10 | ||
| Carbamazepine | 0.025 | 0.00034 | 0.0055–0.0067 | 0.0068–0.0080 | 0.0081–0.0093 | 0.0095–0.0107 | 0.0108–0.0120 | 0.0121–0.0133 | ||
| Atenolol | 20 | 0.0027 | 0.0434–0.0529 | 0.0540–0.0635 | 0.0646–0.0741 | 0.0752–0.0847 | 0.0858–0.0953 | 0.0964–0.1059 | ||
| 17 β -Estradiol | 0.002 | 0.00005 | 0.0008–0.0009 | 0.0010–0.0011 | 0.0012–0.0013 | 0.0014–0.0015 | 0.0016–0.0017 | 0.0018–0.0019 | ||
| Iohexol | 10,000 | 125 | 2009.8–2451.0 | 2500.0–2941.2 | 2990.2–3431.4 | 3480.4–3921.6 | 3970.6–4411.8 | 4460.8–4902.0 | ||
| Iopromide | 370,000 | 83.333 | 1339.9–1634.0 | 1666.7–1960.8 | 1993.5–2287.6 | 2320.3–2614.4 | 2647.0–2941.2 | 2973.8–3268.0 | ||
| Iopamidol | – | – | 118.6 | 1906.9–2325.5 | 2372.0–2790.6 | 2837.1–3255.7 | 3302.2–3720.8 | 3767.3–4185.9 | 4232.4–4651.0 | |
Tolerable daily intake (TDI).
Calculation provided in Supplementary Material.
Fig. 5Recommended treatment methods for HWW remediation based on existing pilot/full-scale units along with their advantages and disadvantages. [Data source: Table S4 in Supplementary Material].
Fig. 6(a) Worldwide BMW generation rate (kg/bed/day) and (b) hazardous and the non-hazardous component of the BMW generated among the selected countries [Data source: Table S4 in Supplementary Material]. (c) Different categories of BMW generated by hospitals based on different international organizations and regulatory authorities, as well as various disposal strategies proposed by them [Data source (MOEFCC, 2016; SANS, 2008; WHO, 2014):].